Precision BioSciences

Precision BioSciences Inventory

The Inventory of Precision BioSciences (DTIL) as of Oct 25, 2026 is 7.55 M USD. In the previous year, Inventory was 17.43 M USD — a change of -56.68% (lower).

Inventory

7.55 MUSD

YoY

-56.68%

Last updated:

Inventory of Precision BioSciences is 2022 7.55 M USD. Inventory of Precision BioSciences was 2021 17.43 M USD. It decreases by -56.68% lower compared to the previous year.

The Precision BioSciences Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
9.50 M USD
Jan 1, 2020
5.76 M USD
Jan 1, 2021
17.43 M USD
Jan 1, 2022
7.55 M USD
The Precision BioSciences Inventory history
YEARInventoryYoY
7.55 MUSD-56.68%
17.43 MUSD+202.57%
5.76 MUSD-39.33%
9.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision BioSciences Stock analysis

What does Precision BioSciences do? Precision BioSciences develops genome editing technologies, focusing on its ARCUS platform for precise DNA modification. The company creates nucleases to insert, remove, and alter DNA at specific genome locations, targeting therapeutic, agricultural, and biologics manufacturing applications. Its product pipeline includes four CAR T cell candidates: PBCAR0191, PBCAR20A, PBCAR269A, and PBCAR371A, designed for allogeneic CAR T immunotherapy. Precision BioSciences generates revenue through licensing ARCUS technology to partners in biopharmaceuticals and agriculture, with product candidates advancing toward clinical and commercial stages. The company targets biopharmaceutical firms seeking advanced genome editing tools for drug development and agricultural companies aiming for sustainable food solutions. ARCUS technology addresses limitations in current editing methods, enabling applications in human disease treatment and agricultural innovation. Precision BioSciences' focus on allogeneic CAR T therapies and in vivo gene correction positions it to serve clients requiring scalable, precise genetic solutions. Precision BioSciences' product candidates span therapeutic, agricultural, and biologics manufacturing segments, with CAR T cell therapies representing a key therapeutic focus. The company monetizes through technology licensing and development partnerships, leveraging its ARCUS platform to develop solutions that overcome existing genome editing constraints. Its pipeline includes both early-stage candidates and those progressing toward clinical validation for human therapeutic use. Precision BioSciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision BioSciences stock

Inventory of Precision BioSciences is 7.55 M USD in 2022.

Inventory of Precision BioSciences changed from 17.43 M USD to 7.55 M USD, representing a -56.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Precision BioSciences since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Precision BioSciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Precision BioSciences

All Key Metrics — Precision BioSciences